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Abstract
Aim : To assess platelet activation in south Indian type 2 diabetic subjects with and without CAD.
Methods : Four groups of subjects were studied; Group 1 comprised of non-diabetic subjects without coronary
artery disease (CAD) (n = 30). Type 2 diabetic subjects without CAD formed Group 2 (n = 30); Group 3
comprised of type 2 diabetic subjects with CAD (n = 30) and Group 4 consisted of non- diabetic subjects with
CAD (n=14). CAD was diagnosed based on coronary angiographic evidence of severe double or triple vessel
disease. Platelet activation was tested after an overnight fast in blood obtained from a bleeding wound at 1
minute post-incision (wound-induced activation) as well as venous blood stimulated in vitro with collagen,
using whole blood flow cytometry. In subjects with CAD, aspirin was withdrawn for 7 days and nitrates for
24 hours.
Results : Collagen induced GP IIb/IIIa binding was significantly higher among diabetic subjects with (28.10
± 19.89; p<0.05) and without CAD (21.02 ± 19.62; p<0.05) and non-diabetic subjects with CAD (23.89 ± 15.65;
p<0.05) compared to non-diabetic subjects without CAD (11.69 ± 13.69). Regression analysis showed collagen
induced GP IIb/IIIa binding to be significantly associated with CAD [odds ratio (OR): 1.029, p = 0.025] and
diabetes (OR: 1.037, p = 0.007).
Conclusion : Increased platelet activation is seen in urban south Indians with diabetes and CAD. ©
and diabetes.10,11 We therefore studied platelet activation,
[P-selectin expression and GP IIb/IIIa binding-anti-
ligand induced binding sites-1 binding (LIBS-1)] in the
whole blood using flowcytometric technique and
compared the same in Asian Indians with and without
diabetes and CAD and this is the first such study to our
knowledge in this population.
MATERIAL AND METHODS
The following age and sex-matched groups of subjects
were studied.
Group 1 composed of 30 non-diabetic subjects without
CAD, selected from an ongoing population based study
- the Chennai Urban Population Study (CUPS), the
details of which are published elsewhere.12 The inclusion
criteria were: normal glucose tolerance, absence of
angina, myocardial infarction or history of any vascular
disease and a normal resting 12 lead ECG.
Groups 2 and 3 consisted of type 2 diabetic subjects
selected from the Dr. Mohan's Diabetes Specialities
Centre, a specialized centre for diabetes at Chennai
(formerly Madras).  Diagnosis of type 2 diabetes was
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Asian Indians have been shown to have much highrates of premature coronary artery disease (CAD)
compared to Europeans1 and Chinese.2 While part of
this is explained by increased insulin resistance3 and
high rates of diabetes,4 these factors do not fully explain
the excess CAD risk in this ethnic group. There are very
few studies in Asian Indians on platelet activation,5
which is an important pathogenic event in
predisposition to CAD6 and it is also associated with
diabetes.7 Studies in western populations have shown
platelet activation to be higher in diabetic subjects
compared to non-diabetic subjects.8 However, there have
been virtually no studies on Asian Indian diabetic
subjects, which is significant as Asian Indians have
greater insulin resistance than Europeans despite being
lean.9 They also have a greater susceptibility to both CAD
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based on the WHO consulting group criteria13 i.e. fasting
plasma glucose ≥ 126 mg/dl and/or 2 hr post glucose ≥
200 mg/dl.
Group 2 included 30 type 2 diabetic subjects without
clinically evident CAD.  All subjects in this group denied
any history of angina, myocardial infarction or any
vascular disease and had normal resting ECGs.
Group 3 comprised of 30 type 2 diabetic patients with
CAD who were diagnosed based on coronary
angiographic evidence of significant (> 70%) stenosis of
two or more coronary arteries.
Group 4 consisted of 14 non-diabetic patients with
CAD (i.e. normal glucose tolerance) diagnosed
angiographically using similar criteria as described for
Group 3.
Age and sex matched subjects for Group 3 and 4 were
recruited with the help of a cardiologist (SA).
Institutional ethical committee approval was obtained
for the study and informed consent was obtained from
all study subjects.
Washout for aspirin therapy and nitrates
As this study deals with platelet activation, washout
of anti-platelet drugs is necessary. All the patients with
CAD subjects for the study who were using anti-platelet
drugs were on aspirin alone. Aspirin is known for its
antiplatelet aggregatory effect through its irreversible
inhibition of platelet cyclooxygenase.14 Since the lifespan
of platelets is 5-7 days, we opted for 7 days wash out for
aspirin. All diabetic and non-diabetic subjects with
CAD who were on aspirin therapy, consented for the
wash out period of 7 days before collecting blood for
platelet activation studies. The pharmacokinetics of
nitrates suggests that the half-life of the nitrates is 5
hours. Hence we decided on a 24-hour washout for
nitrates. All subjects with CAD on nitrates consented
for 24 hours washout.
Anthropometric measurements
Physical examination included height and weight
measurements and the body mass index (BMI) was
calculated.
Biochemical parameters
A fasting blood sample was taken for biochemical
studies. Biochemical analyses were done on Hitachi -
912 Autoanalyser (Hitachi, Mannheim, Germany) using
kits supplied by Roche Diagnostics, (Mannheim,
Germany). Fasting plasma glucose (glucose oxidase-
peroxidase method), serum cholesterol (cholesterol
oxidase-peroxidase-amidopyrine method), serum
triglycerides (glycerol phosphate oxidase-peroxidase-
amidopyrine method) and HDL cholesterol (after
precipitation of LDL and chylomicrons using
phosphotungstic acid) were measured. Low-density
lipoprotein (LDL) cholesterol was calculated using the
Friedewald formula.15 Glycated hemoglobin (HbA1C)
was estimated by high-pressure liquid chromatography
using the Variant machine (Bio-Rad, Hercules, Calif.,
USA).
Platelet activation studies
Whole venous blood, collected in 3.8% sodium citrate,
was added to tubes containing Walsh’s buffer, a
saturating solution of the anti-CD42b antibody and
saturating solutions of one of the two antibodies for
activation detection: AC1.2 PE for detection of P-selection
expression (an indication of platelet secretion); and
biotinylated Anti-LIBS-1, specific for GP IIb/IIIa (ligand)
binding. Negative and positive control tubes were
prepared for each subject, as previously noted 5 and
additional tubes were prepared using 100 mg.ml-1 of
equine collagen, Type 1. A modified bleeding time test
was performed. After inflating a sphygmomanometer to
40 mm Hg for 30-60 seconds, an incision was made using
a Surgicutt R lancet, using moderate pressure. The
incision was allowed to bleed for 1 minute, at which
time a sample was taken using a heparinized capillary
tube to collect all blood present at the incision site.
Following the 1-minute sample, the incision was
bandaged with steristrips. Whole blood collected in
heparinized capillary tubes was added immediately to
similar tubes with one of the two activation antibodies.
All tubes were mixed gently and incubated for 15 min
with labeled antibody. The reaction was then stopped
and the platelets fixed by the addition of 450 ml of 0.25%
paraformaldehyde. Flow cytometric acquisition [Becton
Dickinson Immunocytometry Systems, Belgium] and
analysis was performed within 6 h by a trained operator
blinded to subjects status. Acquisition was limited to
include only particles with the characteristic properties
of platelets and stained for the SZ2-FITC (or SZ2-PE)
antibody. Analytical markers were used to determine
the percentage of activated platelets.
Statistical Analysis
One-way ANOVA or students “t” test as appropriate
was used to compare groups for continuous variables.
Chi-square test or Fisher’s Exact test as appropriate was
used to compare proportions. Regression analysis was
done to determine the association of platelet activation
with diabetes and CAD. All analysis was done using
Windows based SPSS statistical package (Version 10.0,
Chicago) and p values <0.05 were taken as the level of
significance.
RESULTS
Table 1 shows the characteristics of the study
population. Serum cholesterol and triglycerides were
significantly higher among the non-diabetic subjects
with CAD compared to non-diabetic subjects without
CAD.
Table 2 presents the results of platelet activation in
study groups. Both wound induced and collagen
induced P-selectin expression were higher in subjects
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with diabetes both with and without CAD and in non-
diabetic with CAD compared to non-diabetic subjects
without CAD. However, the difference did not reach
statistical significance probably due to the small sample
size.
Collagen induced GP IIb/IIIa binding was
significantly higher among diabetic subjects with and
without CAD (p<0.05) and non-diabetic subjects with
CAD (p<0.05) compared to non-diabetic subjects without
CAD.
Fig. 1 shows the mean values of collagen induced GP
IIb/IIIa binding levels in relation to HbA1c. There was a
significant increase in collagen induced GP IIb/IIIa
binding levels with increase in tertiles of HbA1c
(ANOVA  p=0.026).
Table 3 shows the results of the regression analysis
which showed collagen induced GP IIb/IIIa binding to
be significantly associated with CAD [odd ratio (OR):
1.029, p=0.025]. This association persisted even after
adjusting for HbA1c (OR: 1.026, p=0.050).
Similarly, collagen induced GPIIb/IIIa binding
(unadjusted: OR: 1.037, p=0.007; adjusted: OR: 1.030,
p=0.040) also showed a significant association with
diabetes even after adding CAD as an independent
variable into the regression equation.
DISCUSSION
This study shows that collagen induced GP IIb/IIIa
binding seems to be associated with CAD as well as
diabetes in Asian Indians and that collagen induced GP
IIb/IIIa binding is strongly associated with glycemic
control. These findings are of interest as this study, for
the first time, using specific flowcytometric techniques
demonstrates that platelet activation is associated with
CAD as well as diabetes in this high-risk   population.10,11
Table 1 : Clinical and biochemical characteristics of the study population
Parameters Non-diabetic Type 2 diabetic Type 2 diabetic Non-diabetic
subjects without subjects without subjects with subjects with
CAD (n = 30)  CAD (n = 30)  CAD (n = 30)   CAD (n = 14)
Age (Yrs) 55 ± 8 55 ± 7 55 ± 8 55 ± 13
Body mass index (Kg/m2) 23.8 ± 3.4 25.4 ± 3.3 25.3 ± 3.0 25.9 ± 4.5
Systolic blood pressure  (mm Hg) 126 ± 17 129 ±11 131 ± 12 130 ± 19
Diastolic blood pressure (mm Hg) 80 ± 8 84 ± 4* 84 ± 6* 88 ± 13*
Fasting plasma glucose (mg/dl) 95 ± 11 167 ± 40 * 173 ± 56 * 99 ± 16 #@
HbA1c (%) 5.4 ± 0.4 7.7 ± 1.4 * 8.5 ± 1.7 * 5.5 ± 0.6# @
Serum cholesterol (mg/dl) 154 ± 46 185 ± 31* 192 ± 39* 196 ± 35 *
Serum triglycerides (mg/dl) 124 ± 53 150 ± 69 192 ± 62* 154 ± 69 *
HDL cholesterol (mg/dl) 42 ± 12 43 ± 8 39 ± 8 42 ± 12
LDL cholesterol (mg/dl) 119 ± 31 115 ± 23 119 ± 31 115 ± 46
*p <0.05 compared to non-diabetic subjects without CAD; #p<0.05 compared to type 2 diabetes without CAD; @p<0.05 compared
to type 2 diabetes with CAD
Table 2 : Platelet activation parameters in the study group
Parameters Non-diabetic Type 2 diabetic Type 2 diabetic Non-diabetic
subjects without subjects without subjects with subjects with
CAD (n = 30)  CAD (n = 30)  CAD (n = 30)   CAD (n = 14)
P selectin expression (W) 52.66 ± 16.77 58.41 ± 24.15 57.52 ± 20.86 58.21 ± 18.25
GP IIb/IIIa binding (W) 13.44 ± 10.25 17.76 ± 13.24 17.18 ± 11.01 18.58 ± 5.56
P selectin expression (C) 64.22 ± 23.45 68.54 ± 29.65 69.12 ± 25.76 73.16 ± 21.61
GP IIb/IIIa binding (C) 11.69 ± 13.69 21.02 ± 19.62* 28.10 ± 18.89* 23.89 ± 15.65*
W - Wound induced; C - Collagen induced; * p <0.05 compared to non-diabetic subjects without CAD
Table 3 : Association of collagen induced GP IIb/IIIa
binding with CAD and diabetes - Regression Analysis
OR 95% CI p value
Dependent variable: CAD
GPIIb/IIIa - Collagen induced
Unadjusted 1.029 1.004 - 1.054 0.025
Adjusted for HbA1c 1.026 1.000 – 1.053 0.050
Dependent variable: Diabetes
GP IIb/IIIa - collagen induced
Unadjusted 1.037 1.009 – 1.066 0.007
Adjusted for CAD 1.030 1.001 – 1.059 0.040
Fig. 1 : Mean values of collagen induced GP IIb/IIIa binding in
relation to HbA1c
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Although the prevalence of premature CAD is very
high among Indians, the exact causes of the excess CAD
rates have not been clearly identified. Hence there is a
need to search for newer risk factors. Platelet
hyperactivity has been shown to be associated with
diabetes, myocardial infarction, stroke, emotional stress,
smoking, unstable angina, dyslipidemia and
angioplasty.16,17 Earlier studies by us on platelet activation
factors like sCD40L and sP-selectin indicated increased
platelet activation among diabetic subjects compared to
normals.18 This increase could probably be a reflection
of all the metabolic derangements inclusive of increased
lipids among the diabetic subjects. However, most of
these studies have used methods like platelet
aggregation, radioimmunoassay (RIA) or enzyme linked
immunosorbent assay (ELISA) for detecting platelet
activation. These measures have some limitations, as
artefactual in vitro platelet activation could occur due to
methodological issues. Whole blood flow cytometry has
minimized these problems yielding a method to assess
platelet activation in the physiological milieu of the
blood. In this study we have used flow cytometry to
assess platelet activation dependent increase in P-
Selectin and ligand induced conformational changes in
the GP IIb/IIIa complex using specific antibodies. GP
IIb/IIIa receptor has recently gained a lot of interest in
the field of cardiology and inhibitors against these
receptors are used in treating CAD.19 The CURE study
showed that clopidogrel while prevents expression of
GP IIb/IIIa receptor,20 which is beneficial in subjects with
acute coronary syndrome.21
In this study we used collagen as a stimulus to activate
platelets. In addition, we also used bleeding time or
wound induced platelet activation and assessed GP IIb/
IIIa binding. The wound-induced model has the
advantage of assessing the platelet activation in
response to an in vivo vascular injury.  We found that
both wound and collagen induced GP IIb/IIIa binding
were increased in diabetic compared to non-diabetic
subjects. This is in agreement with earlier findings,
which have shown platelet aggregation and adhesion
to be higher among diabetic subjects compared to
normals.17 The relation of collagen induced GP IIb/IIIa
binding with diabetes was not affected by the presence
of CAD, as observed from the regression analysis,
indicating that diabetes per se also alters platelet
activation. This is in agreement with a recent review,
which suggests that diabetes is a CAD risk equivalent.22
Moreover, these alterations have been shown to be
influenced by blood glucose levels as also shown in the
study in relationship to HbA1c levels.
Collagen induced GP IIb/IIIa binding levels were
higher among subjects with CAD. This finding is of
importance as earlier studies have shown increased GP
IIb/IIIa binding levels in Asian Indians.5 Thus GP IIb/
IIIa binding may be associated with CAD in Indians.
Though HbA1c showed an association with collagen
induced platelet activation, this did not affect its
association with CAD as observed in the regression
analysis.
This study has several limitations. Firstly, the sample
size is rather small, particularly the non-diabetics with
CAD. However it is to be noted that these studies are
extremely labour intensive and expensive and hence had
to be done on small numbers. Secondly, not all platelet
activation measures showed an association with
diabetes or CAD. This could again be an effect of the
small sample size as most measures of platelet activation
were higher in the subjects with diabetes and/or CAD
compared to controls. Thirdly, we were unable to
measure plasma and platelet concentrations of nitric
oxide and lipoxins which would have added more
information on vasodilatation and monocyte adherence,
as these processes are also involved in atherosclerosis.
Finally, a cause and effect relation between platelet
activation and diabetes or CAD cannot be established
due to the cross sectional nature of the study. Further,
we were unable to assess the role of interventions that
could reduce platelet activation. This indicates the need
of future prospective studies in order to establish the
significance of lowering platelet activation with respect
to the reduction of cardiovascular events.
In conclusion the study results indicate that platelet
activation is increased in urban South Indians with both
diabetes and CAD.
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